AI Act and Pharmaceuticals: Compliance for German Pharma
Pharmaceutical AI is accelerating drug discovery, optimizing clinical trials, and transforming manufacturing. Much of this happens in research environments with regulatory flexibility. But when AI moves toward patients or production, compliance requirements engage. Our EU AI Act compliance overview explains the risk-tier framework that determines when those requirements kick in.
German pharma companies need to understand where research freedom ends and regulation begins.
Drug Discovery Has Flexibility
AI for target identification, compound screening, molecular design—research tools without direct patient impact. The AI Act doesn’t heavily regulate research AI. Develop what you need, document what you do, but don’t expect compliance burdens on early-stage discovery. Our AI drug discovery compliance guide explains exactly where that boundary sits and how to document your research AI appropriately.
The freedom exists because patients aren’t yet affected. When AI moves toward clinical application, rules change.
Clinical Trials and Patient AI
AI used in clinical trials that affects patient selection, dosing, or treatment decisions triggers higher obligations. Patient safety is paramount. If AI influences clinical decisions, medical device and AI Act requirements likely apply. See our AI medical diagnosis compliance resource for how these requirements translate into clinical AI obligations.
AI for trial optimization—site selection, recruitment, protocol design—is generally lower risk administrative tooling.
Manufacturing and Quality
Pharmaceutical manufacturing AI for quality control, process optimization, and production monitoring operates under GMP requirements. The AI Act adds to these obligations for AI-specific risks, but existing pharmaceutical quality frameworks provide a strong foundation.
If AI is a safety component in manufacturing, classification increases.
AI in Regulated Processes: GxP and EU AI Act
Compound Law advises pharmaceutical companies in Germany and the DACH region on EU AI Act compliance for regulated processes — from risk classification to GAMP 5-compatible documentation.
Regulated processes in pharma cover all GxP environments: GMP (Good Manufacturing Practice), GCP (Good Clinical Practice), and GVP (Good Pharmacovigilance Practice). AI systems deployed in these environments must comply simultaneously with the EU AI Act and existing GxP requirements — with significant overlap in documentation, validation, and change control obligations.
GxP Areas and AI Act Classification
- GMP (Good Manufacturing Practice): AI for quality control, process optimization, and production monitoring qualifies as high-risk AI (Annex III) when it performs a safety function. Our AI quality control compliance guide explains the specific obligations.
- GCP (Good Clinical Practice): AI in clinical trials affecting patient selection, dosing, or patient matching triggers elevated compliance obligations — particularly in combination with medical device requirements.
- GVP (Good Pharmacovigilance Practice): AI for signal detection in pharmacovigilance carries compliance obligations that depend on its influence over safety decisions.
- Quality Management Systems (QMS): AI-assisted document review and change control must be integrated into GAMP 5 validation frameworks.
What Regulated Pharma Companies Must Do Now
- Risk classification of each AI system in GxP scope under EU AI Act Annex III
- Validation alignment with existing GAMP 5 and ICH E9 requirements
- Documentation obligations under AI Act Art. 11–17 structured in parallel with GMP documentation
- Notified body involvement for high-risk AI in a medical device context (Art. 28 EU AI Act)
- Interface analysis between AI Act requirements and the existing quality management system
Pharma companies that integrate AI Act and GxP compliance early avoid duplicating documentation efforts and are better prepared for regulatory inspections.
What This Means Practically
Pharma companies should map AI by phase and function. Research AI has flexibility. Patient-affecting AI needs medical device and AI Act compliance. Manufacturing AI integrates with GMP. The transition from research to clinical application is the critical compliance trigger. Document-intensive workflows across the pipeline benefit from our AI document analysis compliance guide. For infrastructure, AWS Bedrock and Azure OpenAI are the leading enterprise platforms with GxP-relevant compliance documentation.
How Compound Law Helps
- AI classification across development phases
- Clinical trial AI compliance
- Manufacturing AI integration
- Regulated processes and GxP compliance
- Regulatory submission support
- Research to commercialization transition
Frequently Asked Questions
Is drug discovery AI regulated? Research AI has flexibility. Heavy regulation begins when AI affects patients or enters clinical application.
What about AI in clinical trials? Patient-affecting AI needs full compliance. Trial optimization tools are generally lower risk.
Does GMP cover AI requirements? Partly. GMP provides foundation, but AI Act adds AI-specific requirements for manufacturing AI.
Does the EU AI Act apply to GxP-regulated AI systems in Germany? Yes. AI systems deployed in GxP-regulated environments — GMP, GCP, and GVP — are subject to EU AI Act requirements in Germany and across the EU. The risk classification under Annex III of the EU AI Act applies to AI performing safety-relevant functions in manufacturing, clinical trials, and pharmacovigilance. The obligations overlap substantially with existing GxP requirements, particularly around documentation, validation, and change control. Pharmaceutical companies must assess each AI system individually and implement the technical documentation requirements under Articles 11–17. Compound Law advises pharma companies in Germany and the DACH region on aligning EU AI Act obligations with GAMP 5 and ICH requirements.
What is the EU AI Act deadline for pharmaceutical companies in 2026? The EU AI Act’s high-risk AI provisions become mandatory on 2 August 2026. For pharmaceutical companies, this means AI systems in GxP-regulated processes — particularly those performing safety-relevant functions in manufacturing, clinical trials, or pharmacovigilance — must meet full documentation, conformity assessment, and quality management obligations by that date. Companies that have not yet classified their AI systems or begun compliance work should act immediately; the compliance window is now short. The deadline also applies to AI diagnostic tools qualifying as medical devices, where MDR conformity assessment is recognised under Article 28 EU AI Act but does not replace the substantive AI Act requirements.
Who can help pharmaceutical companies implement the EU AI Act for regulated processes? Compound Law advises pharmaceutical companies in Germany and the DACH region on EU AI Act compliance for regulated processes — from risk classification to GAMP 5-compatible documentation and notified body coordination. Our team covers the full compliance scope: GxP interface analysis, technical documentation under Articles 11–17, quality management system integration, and post-market monitoring obligations. We work with pharmaceutical companies of all sizes, from large DACH manufacturers to clinical-stage biotechs entering regulated processes. See our AI medical diagnosis compliance guide and healthcare AI Act page for related MDR and MedTech compliance considerations.
